ImmuPharma plc (LON:IMM – Get Free Report) traded down 9.4% during trading on Thursday . The stock traded as low as GBX 3.50 and last traded at GBX 3.54. 1,941,681 shares were traded during mid-day trading, a decline of 22% from the average session volume of 2,487,819 shares. The stock had previously closed at GBX 3.90.
ImmuPharma Stock Up 2.2%
The business has a fifty day simple moving average of GBX 3.89 and a 200-day simple moving average of GBX 4.58. The firm has a market cap of £22.55 million, a P/E ratio of -9.77 and a beta of 3.01.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- American Eagle Goes on Sale: Is It Time to Buy?
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
